MANKIND Stock Overview
Develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MANKIND from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Mankind Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,805.20 |
| 52 Week High | ₹2,922.90 |
| 52 Week Low | ₹1,901.05 |
| Beta | 0 |
| 1 Month Change | 9.94% |
| 3 Month Change | 5.85% |
| 1 Year Change | 45.10% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 97.23% |
Recent News & Updates
Here's Why Mankind Pharma (NSE:MANKIND) Can Manage Its Debt Responsibly
Dec 04
Mankind Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08Recent updates
Here's Why Mankind Pharma (NSE:MANKIND) Can Manage Its Debt Responsibly
Dec 04Mankind Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08Here's Why Mankind Pharma (NSE:MANKIND) Can Manage Its Debt Responsibly
Aug 26Risks To Shareholder Returns Are Elevated At These Prices For Mankind Pharma Limited (NSE:MANKIND)
Jul 12Here's Why Mankind Pharma (NSE:MANKIND) Has Caught The Eye Of Investors
May 08Mankind Pharma Limited's (NSE:MANKIND) Business Is Trailing The Market But Its Shares Aren't
Apr 08Mankind Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 04Shareholder Returns
| MANKIND | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 6.2% | 0.8% | -4.2% |
| 1Y | 45.1% | 39.7% | 19.1% |
Return vs Industry: MANKIND exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: MANKIND exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| MANKIND volatility | |
|---|---|
| MANKIND Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: MANKIND has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: MANKIND's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 19,540 | Sheetal Arora | www.mankindpharma.com |
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations.
Mankind Pharma Limited Fundamentals Summary
| MANKIND fundamental statistics | |
|---|---|
| Market cap | ₹1.12t |
| Earnings (TTM) | ₹21.15b |
| Revenue (TTM) | ₹110.18b |
53.1x
P/E Ratio10.2x
P/S RatioIs MANKIND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MANKIND income statement (TTM) | |
|---|---|
| Revenue | ₹110.18b |
| Cost of Revenue | ₹33.63b |
| Gross Profit | ₹76.55b |
| Other Expenses | ₹55.40b |
| Earnings | ₹21.15b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 52.79 |
| Gross Margin | 69.47% |
| Net Profit Margin | 19.20% |
| Debt/Equity Ratio | 4.4% |
How did MANKIND perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 14:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mankind Pharma Limited is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| null null | Antique Stockbroking Ltd. |